Home Overview Press Room Blog Publications For Students about us

Personal genomics : Displaying 225-244 of 705

Aiming to Push Genomics Forward in New Studyby Andrew PollackNew York TimesJanuary 13th, 2014Regeneron Pharmaceuticals, a fast-growing biotech company, is undertaking an ambitious new genomics effort with a health care provider that treats 3 million people in Pennsylvania.
Testing times for the consumer genetics revolutionby Donna DickensonNew ScientistJanuary 13th, 2014With the highest-profile seller of $99 genetic tests under fire, will public trust in personalised medicine suffer?
After 23andMe, Another Personal Genetics Firm Is Charged with False Advertisingby Dina Fine MaronScientific AmericanJanuary 11th, 2014The Federal Trade Commission says GeneLink, which served 30,000 customers, made claims not based on science and failed to protect consumer information.
Some Data, PleaseGenome WebJanuary 8th, 2014The US Federal Trade Commission cracks down on companies making deceptive claims about their genetically tailored nutritional supplements and skincare products.
Genetic Testing Sparks Ethics Debate[With CGS's Marcy Darnovsky]CCTV AmericaJanuary 5th, 2014Mark Niu reports on the ethical debate surrounding genetic testing and the FDA's ruling on 23andMe.
I Had My DNA Picture Taken, With Varying Resultsby Kira PeikoffThe New York TimesDecember 30th, 2013Kira Peikoff had her DNA tested by three direct-to-consumer companies, and the results didn't agree.
Biopolitical News of the Year 2013by Pete ShanksBiopolitical TimesDecember 19th, 2013For better and worse, 2013 has been a year in which several related issues familiar to those who follow human biotechnology moved into the wider sphere of public discussion.
Ensure That Genetic Tests are Accurate: Our Viewby The Editorial BoardUSA TodayDecember 16th, 2013Opening the door to genetic testing and its potential health benefits is an exciting prospect. But only if the tests are accurate, the interpretations meaningful, and the results understandable.
Medics should plan ahead for incidental findingsby Erika Check HaydenNature NewsDecember 12th, 2013The US Bioethics Commission weighs in on the debate over how scientists and companies should handle inadvertent discoveries in diagnostic tests.
The Case for a New Biopoliticsby Marcy DarnovskyYouTubeDecember 11th, 2013A talk at UC Berkeley Extension for Leonardo Art Science Evening Rendezvouz (LASERs), a national program of evening gatherings that bring artists and scientists together for informal presentations and conversation with an audience.
Singularity: Reading our genes like computer code[Quotes CGS's Marcy Darnovsky]by Jane WakefieldBBC NewsDecember 9th, 2013Marcy Darnovsky tells the BBC: "It's becoming ever more clear that genetic information will never yield solid actionable data about an individual's risks for the vast majority of common complex diseases."
Utah’s Myriad Genetics Ramps up Gene Patenting Disputeby Tom HarveyThe Salt Lake TribuneDecember 9th, 2013Myriad Genetics is enveloped in a spate of lawsuits over its gene patents, this time sparring with companies that want to erode its dominant position in testing genes related to breast and ovarian cancer.
Genetic Tester to Stop Providing Data on Health Risksby Andrew PollackThe New York TimesDecember 6th, 2013Bowing to the Food and Drug Administration, 23andMe said it would stop providing consumers with health information while its test undergoes regulatory review.
23andMe's Troubles: The Spat over Spit by Pete ShanksBiopolitical TimesDecember 5th, 2013First a warning letter from the FDA, then a class action lawsuit. What's next for Google-backed 23andMe, the only direct-to-consumer genetic testing company still in the game?
Die, Selfish Gene, Dieby David DobbsAeon MagazineDecember 3rd, 2013How vital, really, are actual changes in the genetic code? Do we even need DNA changes to adapt to new environments? Is the importance of the gene as the driver of evolution being overplayed?
The Failed Promise of 23andMeby Robert KlitzmanBloombergDecember 3rd, 2013The FDA should take stronger action to protect consumers from the risks associated with direct-to-consumer testing - especially overpromises about partial testing.
San Diego Woman Sues 23andMe Over DNA Testby Gary RobbinsUT San DiegoDecember 3rd, 2013A class-action lawsuit alleges that 23andMe knowingly misled consumers into thinking that its DNA test kits produce a reliable look at a person’s relative risk for hundreds of diseases and disorders.
Genetic Testing Should Adhere to Medical, Not Business, Ethics: FDA's Regulation of 23andMe Is a Welcome Move for Consumersby Karuna JaggarHuffington PostDecember 1st, 2013The truth is that we still understand very little about how our genes interact with our environment, and our individual choices, to impact our health.
23andMe Is Terrifying, But Not for the Reasons the FDA Thinksby Charles SeifeScientific AmericanNovember 27th, 2013As the FDA frets about the accuracy of 23andMe’s tests, it is missing their true function, and consequently the agency has no clue about the real dangers they pose.
Personalized Cancer Treatments Suffer Setbackby Erika Check HaydenNatureNovember 27th, 2013Much hope has been placed on therapies that play on the same mutations that make cells cancerous — but selecting the right drugs may be more complicated than expected.
Displaying 225-244 of 705  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760